Search - tctmd.com

Displaying 41 - 56 of 56

Sort: Relevancy | Date

News Conference News ACC 2020

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

Yael L. Maxwell

March 28, 2020

News Conference News ACC 2020

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

L.A. McKeown

March 28, 2020

News Opinion Conversations in Cardiology

Conversations in Cardiology: Uncovered Struts on OCT After 12 Years?

March 27, 2020

News Daily News

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

Todd Neale

March 16, 2020

News Daily News

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

Michael O'Riordan

March 11, 2020

News Daily News

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

Yael L. Maxwell

March 10, 2020

News Daily News

New ABCD-GENE Score Taps Clinical, Genetic Factors to ID Clopidogrel Nonresponders

Yael L. Maxwell

March 06, 2020

News Daily News

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

Caitlin E. Cox

March 02, 2020

News Daily News

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

Shelley Wood

February 28, 2020

News Daily News

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Yael L. Maxwell

February 28, 2020

News Conference News CRT 2020

Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation

Michael O'Riordan

February 26, 2020

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

L.A. McKeown

February 11, 2020

News Daily News

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

Shelley Wood

January 20, 2020

News Daily News

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Todd Neale

January 15, 2020

Presentation

Ticagrelor vs Clopidogrel in Patients With ACS Undergoing PCI

January 15, 2020

Presentation CACI 2019

Tratamiento antiagregante en el SCA Resultados del Estudio ISAR REACT 5

Presenter: Carlos Fernandez Pereira

November 29, 2019

Advertisement

Genotype-Based P2Y12 Prescribing Post-PCI Falls Short in TAILOR-PCI

VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events

Conversations in Cardiology: Uncovered Struts on OCT After 12 Years?

More Support for DOAC-Based Double Therapy After PCI for A-fib Patients

Late Cerebrovascular Events ‘Devastating’ in TAVR-Treated Patients

Potent Antithrombotic Therapy Cuts Spontaneous MI After PCI for ACS

New ABCD-GENE Score Taps Clinical, Genetic Factors to ID Clopidogrel Nonresponders

Antiplatelets Add Risk in Newly Diagnosed A-fib Patients: GARFIELD-AF

New Meta-analysis Supports NOAC Plus P2Y12 Inhibitor for PCI in A-fib

Bioprosthetic Valve Thrombosis Rare but Not Benign: New Insights

Less Leaflet Thrombosis in Low-Risk TAVR Patients Treated With Oral Anticoagulation

Outcome Differences Between Men and Women With PAD: EUCLID Insights

Clopidogrel Interaction With Morphine in ACS Linked to More Ischemic Events

No Fewer MACE With Ticagrelor vs Clopidogrel in ACS Patients After PCI: Registry

Ticagrelor vs Clopidogrel in Patients With ACS Undergoing PCI

Tratamiento antiagregante en el SCA Resultados del Estudio ISAR REACT 5

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content